APA (7th ed.) Citation

Fujiki, S., Iijima, K., Okabe, M., Niwano, S., Tsujita, K., Naito, S., . . . Takeishi, Y. (2020). Placebo-Controlled, Double-Blind Study of Empagliflozin (EMPA) and Implantable Cardioverter-Defibrillator (EMPA-ICD) in Patients with Type 2 Diabetes (T2DM): Rationale and Design. Diabetes Therapy, 11(11), 2739. https://doi.org/10.1007/s13300-020-00924-9

Chicago Style (17th ed.) Citation

Fujiki, Shinya, et al. "Placebo-Controlled, Double-Blind Study of Empagliflozin (EMPA) and Implantable Cardioverter-Defibrillator (EMPA-ICD) in Patients with Type 2 Diabetes (T2DM): Rationale and Design." Diabetes Therapy 11, no. 11 (2020): 2739. https://doi.org/10.1007/s13300-020-00924-9.

MLA (9th ed.) Citation

Fujiki, Shinya, et al. "Placebo-Controlled, Double-Blind Study of Empagliflozin (EMPA) and Implantable Cardioverter-Defibrillator (EMPA-ICD) in Patients with Type 2 Diabetes (T2DM): Rationale and Design." Diabetes Therapy, vol. 11, no. 11, 2020, p. 2739, https://doi.org/10.1007/s13300-020-00924-9.